-+ 0.00%
-+ 0.00%
-+ 0.00%

Barclays Upgrades Summit Therapeutics to Equal-Weight, Raises Price Target to $18

Benzinga·12/17/2025 14:45:39
Listen to the news
Barclays analyst Etzer Darout upgrades Summit Therapeutics (NASDAQ:SMMT) from Underweight to Equal-Weight and raises the price target from $16 to $18.